As compared with placebo, non-selective and highly selective SGLT2 inhibitors were associated with significantly higher risk of diabetic ketoacidosis (OR, 3.08; 95% CI, 1.23–7.74 vs. OR, 2.58; 95% CI, 1.31–5.09; p = 0.88) and genital infections (OR, 3.41; 95% CI, 2.41–4.82 vs. OR, 4.54; 95% CI, 2.75–7.47; p = 0.47), respectively, to a similar extent (Fig. 4 and Supplementary Figs. 5, 6). Here, SLC5A2 is linked to diabetic ketoacidosis.